Literature DB >> 27965188

Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy.

Shigeto Yanagihara1, Kazunari Sugita2, Yuichi Yoshida2, Daisuke Tsuruta3, Osamu Yamamoto2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27965188     DOI： 10.1684/ejd.2016.2939

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  6 in total

1.  Interleukin-17 Inhibitor Combination Therapies for the Treatment of Psoriasis: A Systematic Review.

Authors:  Amylee Martin; Akshitha Thatiparthi; Jeffrey Liu; Jashin J Wu
Journal:  J Clin Aesthet Dermatol       Date:  2022-06

2.  Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.

Authors:  Matteo Megna; Cataldo Patruno; Maria Rita Bongiorno; Alessio Gambardella; Claudio Guarneri; Paolo Romita; Annunziata Raimondo; Francesco Loconsole; Gabriella Fabbrocini
Journal:  Clin Drug Investig       Date:  2022-05-28       Impact factor: 3.580

3.  An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis.

Authors:  Yuta Koike; Yumi Fujiki; Maho Higuchi; Reika Fukuchi; Sayaka Kuwatsuka; Hiroyuki Murota
Journal:  JAAD Case Rep       Date:  2019-01-25

Review 4.  Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations.

Authors:  Christos Koutsianas; Konstantinos Thomas; Dimitrios Vassilopoulos
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-03-16       Impact factor: 5.346

5.  Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption.

Authors:  Anna Campanati; Elisa Molinelli; Valerio Brisigotti; Donatella Brancorsini; Ivan Bobyr; Federico Diotallevi; Giulia Radi; Annamaria Offidani
Journal:  Case Rep Dermatol       Date:  2019-09-23

Review 6.  Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.

Authors:  Shintaro Akiyama; Thomas G Cotter; Atsushi Sakuraba
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.